24 Facts About Julio Montaner

Julio S G Montaner was born on April 13,1956 and is an Argentine-born Canadian physician, professor and researcher.

Julio Montaner is known for his work on HAART, a role in the discovery of triple therapy as an effective treatment for HIV in the late 1990s, and a role in advocating the "Treatment as Prevention" Strategy in the mid-2000s, led by Myron Cohen of the HPTN 052 trial.

Julio Montaner completed his residency at the University of British Columbia in the Department of Internal Medicine and Respiratory Medicine and was appointed Chief Resident for the Department of Medicine from 1986 to 1987.

Julio Montaner encountered the opportunity to test AZT monotherapy for HIV as part of his work on PCP, which sparked an interest in HIV research.

Julio Montaner was the only member of the HIV department at St Paul's Hospital when it was first founded.

Julio Montaner became the founding co-director of the Canadian HIV Trials Network in 1990 with Martin Schechter.

Julio Montaner was appointed a National Health Research Scholar of Canada from 1988 to 1998.

In 1996, Julio Montaner presented the results of his pioneering research on triple therapy to treat HIV infections at the XI International AIDS Conference in Vancouver, creating new standard for HIV drug therapy.

Julio Montaner served as the president of the International AIDS Society from 2008 to 2010, and as of 2013, continues to serve as an elected member of the Council of the International AIDS Society after his term as president ended.

Julio Montaner participated in and led a series of studies on the role of adjunctive corticosteroids in treating Pneumocystis carinii pneumonia patients.

At the XI International AIDS Society-USA Conference in 1996, Julio Montaner presented the findings of the INCAS group, which consisted of HIV-positive cohorts in Italy, Netherlands, Canada, Australia and the United States.

Julio Montaner announced an association between decreased viral load and improved outcomes, as well as decreased mortality.

Julio Montaner was coauthor on Robert Hogg's paper demonstrating that resistance to NNRTIs resulted in greater mortality than the development of resistance to protease inhibitors.

Julio Montaner was central in the creation and implementation of the Treatment as Prevention strategy.

Julio Montaner's research addressed concerns of HIV drug resistance evolving from increased and early access to HAART by citing evidence from studies supporting the idea that fears of drug resistance should not prevent widespread HAART distribution.

Julio Montaner is a proponent of harm reduction policy and played a minor role for his colleagues at the BC-CfE, was involved in founding and supporting the Insite Safe Injection facility in Vancouver's Downtown East-Side.

Julio Montaner has co-authored many studies on the effect of safe injection facilities on drug overdoses and deaths, HIV and Hepatitis C infections and the spread of other blood-borne pathogens.

Julio Montaner is being sued by former colleagues for blocking access to data mutually collected.

Julio Montaner is focusing on optimizing HAART treatment and authoring further studies on the "Treatment as Prevention" strategy.

Julio Montaner is working on improving the engagement and treatment of hard-to-reach or rural HIV positive populations as part of a $48 million grant from the Ministry of Health of the Province of British Columbia.

In 2005, Julio Montaner was central in the battle to obtain experimental drugs to treat Vancouver artist and activist Tiko Kerr.

Julio Montaner pressured Health Canada to allow Kerr and five other patients with drug-resistant HIV to receive two experimental HIV drugs, TMC114 and TMC125.28 The drugs had not yet been released to market in Canada due to concerns about drug toxicity.

Julio Montaner argued for access to the drugs under ground of compassionate use.

Kerr credits Julio Montaner with saving his life due to his efforts in obtaining the drugs.